Altay Therapeutics, RADD Pharmaceuticals,
Rubik Therapeutics, VastBiome and Waypoint Bio to receive free year
of lab bench use and other amenities at prominent bioscience
incubators
Bristol Myers Squibb Company (NYSE:BMY) today announced five
innovative biotech startups as winners of the company’s 2021 Golden
Ticket Contests. The winners are: RADD Pharmaceuticals and Rubik
Therapeutics (LabCentral, Cambridge, MA), Waypoint Bio
(BioLabs@NYULangone, New York, NY) and Altay Therapeutics and
VastBiome (MBC BioLabs, San Francisco Bay Area, CA).
“These Golden Tickets are an important way for us to foster
growth of life science startup companies and bolster the
communities in which we work and live,” said Kristen Hege, M.D.,
Senior Vice President, Early Clinical Development,
Hematology/Oncology and Cell Therapy and San Francisco site head.
“A core part of our philosophy is to encourage interdisciplinary
collaborations and novel approaches. Our goal is that BMS’ general
support of the three incubators and our specific contribution to
companies within them will help spur the next wave of scientific
breakthroughs that lead to development of new medicines that
improve the lives of people with serious diseases.”
Bristol Myers Squibb has annually held the Golden Ticket contest
since it began in Cambridge in 2016 for promising biotech start-ups
pursuing research in novel target identification, drug delivery,
discovery technology platforms or translational R&D in a
variety of therapeutic research fields. The Golden Ticket contest
provides recipient companies with one year of fully equipped,
permitted and supported lab space for biomedical research, plus
programming and networking opportunities through these incubators
to help advance their science and build their companies.
About This Year’s Winning Companies
Altay Therapeutics, founded by Ali Rayet Ozes, Ph.D., and Osman
Nidai Ozes, Ph.D., in 2019, is a preclinical-stage drug discovery
company that is working to develop therapies by targeting
disease-causing transcription factors (TFs).
The company’s platform technology enables discovery of small
molecule binding sites within intrinsically disordered domains. The
company has completed proof-of-concept studies by developing
first-in-class inhibitors targeting previously undruggable TFs for
the treatment of idiopathic pulmonary fibrosis (IPF), Ewing’s
Sarcoma, prostate cancer and facioscapulohumeral muscular dystrophy
(FSHD). Altay Therapeutics now is testing the efficacy of its
compounds by collaborating with world-class experts at Georgetown
University, Saint Louis University School of Medicine and
University of California San Francisco. Based on insights gained
from its platform, the company is targeting numerous other
disease-causing TFs to develop more specific therapies and improve
the quality of life for larger patient populations.
RADD Pharmaceuticals is focused on previously undrugged
cancer targets. The startup is backed by the early-stage venture
capital firm Canaan.
Rubik Therapeutics, co-founded by Murray Robinson, Ph.D., in
2021, is on a mission to develop best-in-class engineered cell
therapies for solid tumors by leveraging its data-driven discovery
platforms. The company is backed by Illumina Accelerator.
VastBiome, founded by Kareem Barghouti, MBA, Kovi Bessoff, M.D.,
Ph.D., Peter McCaffrey, M.D., and Ayin Vala, M.S., in 2019, is a
DNA-first drug discovery company mapping the human gut microbiome
to make medicines. The company accesses small molecules produced
from the gut and uncovers their function. VastBiome is using
proprietary methods in genomic sequencing, artificial intelligence
and synthetic biology to discover biomarkers and novel therapeutics
for the most challenging immunologic disorders. The company’s
collaborators include a number of leading institutions such as the
Cleveland Clinic, Moffitt Cancer Center and Baylor College of
Medicine.
Waypoint Bio, founded by David Phizicky, Ph.D., and Xinchen
Wang, Ph.D., in 2021, is a startup working to develop novel
approaches to treat dosage-sensitive diseases such as
haploinsufficiencies. Waypoint is building a genomics and
machine-learning platform for high-throughput screening that can
extract high-dimensional multiplexed cellular features. Their
platform enables profiling of cellular processes linked to gene
dosage that are unobservable by other screening approaches.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, Twitter, YouTube, Facebook and
Instagram.
Celgene and Juno Therapeutics are wholly owned subsidiaries of
Bristol-Myers Squibb Company. In certain countries outside the
U.S., due to local laws, Celgene and Juno Therapeutics are referred
to as, Celgene, a Bristol Myers Squibb company and Juno
Therapeutics, a Bristol Myers Squibb company.
About LabCentral (Cambridge, MA)
A private, non-profit institution, LabCentral was founded in
2013 as a launchpad for high potential life-sciences and biotech
startups. Operating a total of 150,000 square-feet in the heart of
Kendall Square in Cambridge, Mass., LabCentral offers fully
permitted laboratory and office space for as many as 70 startups
comprising approximately 500 scientists and entrepreneurs. For more
information, visit www.labcentral.org or Twitter.
About BioLabs@NYULangone (New York, NY)
BioLabs New York has partnered with NYU Langone Health to build
a unique biotech co-working facility in Manhattan to attract the
best companies in early-stage life sciences and help them scale in
a fraction of the time it would take a company working out of a
traditional co-working space. This is done by providing a
collaborative space, top-of-the-line research equipment, business
support and acceleration programming. BioLabs@NYULangone helps its
residents forge the connections that can take business and science
goals to the next level. Its roster of diverse resident companies
reap the benefits of an unparalleled location in the heart of Soho
and Hudson Square, experienced technical support, a collaborative
community and Startup NY Tax free zone.
About MBC BioLabs (San Francisco, CA)
MBC BioLabs is dedicated to helping life-science startups
succeed. By renting space as small as a single bench and providing
these entrepreneurial scientists with access to millions of dollars
of equipment, MBC BioLabs allows companies to be fast, focused, and
frugal. It has three sites: one in the Dogpatch neighborhood in San
Francisco and two campuses in San Carlos, Calif. Each site has a
complete molecular biology core facility that allows companies to
do experiments on day one. MBC BioLabs has partnerships with
leading pharmaceutical and life-science companies as well as a
built-in venture capital firm, Mission BioCapital. These
partnerships provide entrepreneurs with valuable insights about
where to focus their efforts and accelerates the innovation
pipeline. Since opening in 2013, MBC BioLabs has helped launch and
grow 230 companies. These companies have brought 54 programs to the
clinic, produced 13 approved diagnostics, and raised over $10
billion.
CorporateFinancial_News
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211118005262/en/
Bristol Myers Squibb
Media Inquiries: media@bms.com
Investors: Tim Power 609-252-7509
Timothy.Power@bms.com
Nina Goworek 908-673-9711 Nina.Goworek@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024